Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest radiation therapy Stories

2013-09-24 13:18:13

Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found. The study also found that the medication may be associated with a higher risk of diarrhea than a placebo when used during radiation therapy to the pelvis. The results were presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual...

2013-09-24 12:28:17

DALLAS and NEW YORK, Sept. 24, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, announced a poster presentation at the American Society for Radiation Oncology Meeting, September 22-25, 2013, in Atlanta, GA. The poster presentation, co-authored by Access Pharmaceuticals' Senior Vice President Research and Development, Dr. David Nowotnik, entitled, "Results from the Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled...

2013-09-24 11:18:06

Analysis of patient subset from RTOG 9202 A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. Men with advanced prostate...

2013-09-23 16:24:20

GALVESTON, Texas, Sept. 23, 2013 /PRNewswire/ -- Today, Chrysalis BioTherapeutics, Inc., announced receipt of a $1.5m contract from the National Cancer Institute (NCI) to continue its development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. Radiotherapy is a primary tool for controlling tumor growth, yet damage to surrounding normal tissues limit the amount of radiation that can be used to kill tumors. Moreover, side-effects of radiotherapy can have...

2013-09-23 16:24:08

ATLANTA, Sept. 23, 2013 /PRNewswire/ -- ASTRO Booth #1115 -- The American Board of Radiology Foundation (ABRF) and Varian Medical Systems (NYSE: VAR) today announce that Varian is awarding a $100,000 second year renewal grant to the ABRF, to continue its work establishing a national brachytherapy registry. The registry, which is the first such nationwide modality-based project in radiation oncology, is linked to the American Board of Radiology's (ABR's) Innovation Pathway in...

2013-09-23 13:58:38

Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The Radiation Oncology Therapy Group (RTOG) Community Clinical Oncology Program (CCOP)-supported multi-institutional study screened 455 patients receiving radiation treatment at 37 centers around the U.S. Participants in the...

2013-09-23 13:16:47

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting. The study confirmed a disease-specific-survival (DSS) rate of 95 percent when patients received fewer weeks of neoadjuvant (NEO) total...

2013-09-23 13:14:45

Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The single-arm, phase II study was a multi-institutional, international clinical trial in the U.S. and Canada, conducted through the Radiation Therapy...

2013-09-23 13:13:29

Analysis of RTOG 0617 trial evaluates the impact of high-dose radiation therapy An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual...

2013-09-23 13:06:32

Guideline provides detailed direction on treatment options for prostate cancer patients The American Society for Radiation Oncology (ASTRO) will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO’s 55th Annual Meeting, September 22-25, 2013, in Atlanta. The guideline focuses on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence, and is a joint effort between...